Efficacy and safety of linagliptin in 2681 Asian patients stratified by age, obesity, and renal function: A pooled analysis of randomized clinical trials
Advances in Therapy Aug 21, 2017
Ning G, et al. – The efficacy and safety of the dipeptidyl peptidase–4 inhibitor linagliptin were examined in Asian patients stratified by age, obesity, and renal function. Outcomes approved that linagliptin effectively reduced hyperglycemia in Asian patients with uncontrolled type 2 diabetes (T2D), irrespective of age, BMI, renal function, or ethnic subgroups, and was well tolerated.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries